Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Seltorexant in Renal Impairment
NCT04616677Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of seltorexant in major depressive disorder (MDD) and Insomnia (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration, Area Under Plasma Analyte Concentration versus Time Curve from Time 0 to Time of Last Measurable Concentration and 1 more. Started Mar 2021; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT04616677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616677.